This section keeps you updated throughout the course of the TIMESPAN project.
Blog
-
2 April 2025
TIMESPAN Joins the EMA Catalogue of Real-World Data
Read article …We are excited to announce that TIMESPAN has been officially registered as a network in the Catalogue of Real-World Data (RWD). But why does this matter? Let me explain why we think this is an important step toward improved methodological standards and governance principles for pharmacoepidemiology studies on ADHD.
-
26 March 2025
Join us for an insightful Public Engagement Event in London
Read article …Ever feel like research happens in a bubble, far away from the real experiences of patients? This event is about changing that.
-
20 March 2025
It’s all in the data: Consumer smartwatch vs. medical device
Read article …Typical consumer wearables have been designed to help encourage the general wellness of their wearers, and are increasingly beginning to advertise advanced health-tracking capabilities.
-
13 March 2025
March is Women’s History Month and so we would like to acknowledge Five Women Who Have Inspired an ADHD Charity: Empowering Lives Through Research and Advocacy
Read article …Attention Deficit Hyperactivity Disorder (ADHD) is a complex neurodevelopmental condition that affects millions of individuals worldwide. ADDISS is a charity that, over 30 years, has been dedicated to supporting those impacted by ADHD and providing evidence-based information. A key component of our success has been the contribution of brilliant scientists and researchers who have dedicated their careers to understanding ADHD and improving the lives of those with the condition. We would like to focus on five trailblazing women who stand out for their outstanding contributions to the field of ADHD research.
-
4 March 2025
World Obesity Day Europe: Addressing the Stigma Linking ADHD and Obesity
Read article …The EU TIMESPAN Project is working at the intersection of obesity and other cardiometabolic diseases, and adult attention-deficit / hyperactivity disorder (ADHD), which emerging evidence suggests have shared genetic traits. Obesity and ADHD are both stigmatised conditions. This stigmatisation creates significant barriers to effective treatment and quality of life.
-
26 February 2025
Launch of the Lancet Psychiatry Series on ADHD: A New Era of Global Insights and Action
Read article …The Lancet Psychiatry Series on Attention-Deficit/Hyperactivity Disorder (ADHD) represents a groundbreaking milestone in the field of mental health. As the first-ever Lancet Psychiatry Series dedicated to ADHD, it brings together the latest evidence, clinical expertise, and policy recommendations to improve the lives of individuals with ADHD worldwide.
-
20 February 2025
Junior doctor leads new research about ADHD medicines and pregnancy
Read article …Research that started as a student project has provided new evidence to guide use of ADHD medicines in pregnancy. Dr Andrea Sit, a junior medical doctor and recent Masters of Public Health (MPH) graduate, began the project as part of her MPH in late 2023 and it was published as a preprint late last year.
-
14 February 2025
The SAGA Cohort study is an Icelandic study on the impact of trauma on women’s health
Read article …The SAGA Cohort study is a unique nationwide Icelandic study on the impact of trauma on women‘s physical and mental health, including ADHD and cardiometabolic disorders. The SAGA Cohort is conducted by the TIMESPAN partner at the University of Iceland.
-
12 February 2025
The Promise of AI and Brain Imaging for ADHD Diagnosis: When and How Do We Get There?
Read article …Diagnosing attention-deficit/hyperactivity disorder (ADHD) has long relied on self-reported symptoms, clinical observations, and standardized rating scales like the DSM-5 criteria. However, these assessments are prone to bias, subjectivity, and variability across clinicians and patients, leading to delayed or missed diagnoses, particularly among girls, whose symptoms often go unrecognized. Without timely diagnosis and intervention, untreated ADHD can result in academic struggles, social difficulties, and long-term mental health challenges.
-
29 January 2025
Global Insights: Harnessing Healthcare Data for ADHD Research in TIMESPAN
Read article …ADHD affects millions of individuals worldwide, yet how it is managed and treated can vary dramatically depending on where a patient lives. TIMESPAN is investigating that by harnessing a multi-national platform with healthcare data, paving the way for groundbreaking advancements in ADHD research and patient care.
-
24 January 2025
High genetic risk of ADHD is linked to health risks in adults without ADHD diagnosis: Insights from the Estonian Biobank
Read article …The Estonian Biobank (EstBB) is a large volunteer-based biobank, representing 20% of Estonia’s adult population. Linked to national electronic health records, it allows to study millions of genetic variants alongside up to 20 years of health data from over 212,000 participants. This provides a unique opportunity to uncover how genetics is associated with health outcomes.
-
16 January 2025
ART-CARMA Achieves Recruitment Milestone!
Read article …We are thrilled to announce the successful completion of recruitment for The ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA) Project!
-
9 January 2025
New systematic review on medication adherence in people with ADHD
Read article …Did you know that many kids with ADHD don’t stick to their medication? This can affect their long-term outcomes. Let’s talk about ways to improve adherence!
-
20 December 2024
WP4 paper finally submitted!
Read article …Finally submitted! 🎉 We are excited to soon share our research on how genetics contribute to medication discontinuation in ADHD.
Stimulant medications are the first-line treatment for ADHD, but over 50% of individuals discontinue them within two years. Our study, involving 18,362 individuals from the iPSYCH cohort, aimed to uncover the genetic factors behind this.
-
12 December 2024
New Insights on Long-Term ADHD Treatment and Its Link to Cardiovascular Disease
Read article …ADHD medications, particularly stimulants like methylphenidate and amphetamines, are widely recognized for their effectiveness in managing ADHD symptoms. However, they are also known to increase heart rate and blood pressure in the short term. With a growing number of adults being diagnosed and prescribed these medications for extended periods, questions about adherence patterns and safety, particularly potential risks of cardiovascular disease (CVD), have become increasingly relevant. As individuals with ADHD age and their risk for CVD naturally rises, robust evidence is crucial to guide safe and effective long-term treatment strategies.
-
4 December 2024
The value of pre-registration in psychiatric research.
Read article …The value of open science and reproducible research has been increasingly recognized in contemporary psychiatric research. It is also a key component of TIMESPAN. We aim for pre-registration of protocols on relevant platforms along with the final version of the R code (e.g., https://osf.io/). Our open science strategy also highlight the value of providing a description of how to access raw data for each data source (with online materials typically included in data sharing statements), and whenever possible, presenting aggregated raw data for all study variables in the appendix of publications.